Engineers antibody drugs using its Xtend and bispecific technology, licensed to pharma partners and developed internally.
Engineers antibody drugs using its Xtend and bispecific technology, licensed to pharma partners and developed internally.
Collects royalties on partners' approved drugs that use its Xtend technology, which keeps antibodies in the blood longer, such as Ultomiris from AstraZeneca's Alexion and Monjuvi from Incyte, plus milestone payments on others. It spends that cash on its own cancer and autoimmune antibody drugs.
Moat: narrow (IP / patents, process know-how). Widely licensed Xtend antibody engineering technology embedded in multiple approved partner drugs generates royalties.
Headquarters: Pasadena, California, US · Founded: 1997 · Employees: 260
Size Xencor (XNCR) is a United States Health Care company (Biotechnology) with a market value of $2.58B, the 1628th largest of 3,085 United States companies the cockpit tracks. Shares closed at $34.39 on 18 Nov 2026.
Performance Over six months the shares gained 203.8%, against -4.6% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 33.5% over the last twelve months (peer median +9.4%); the operating margin is -72.7% (peer median -2.6%).
Valuation It trades at 11.7× enterprise value to sales against a peer median of 7.7× (7th most expensive of 17).
Capital Return on invested capital runs 45.3 points below its cost of capital (8.8% WACC).
Short interest Short interest is 17.2% of the free float (30 Oct 2026).
Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $200M | $126M | $110M | $175M | $165M |
| Revenue growth | — | +14% | -37% | +6% | — |
| Gross profit | $191M | $115M | $98.4M | $163M | $156M |
| EBITDA | -$136M | -$167M | -$166M | -$121M | -$72.2M |
| Net income | -$118M | -$91.9M | -$233M | -$133M | -$55.2M |
| Free cash flow | -$176M | -$138M | -$208M | -$96.4M | -$14.0M |
| Capital expenditure | $4.09M | $3.15M | $9.51M | $21.3M | $43.4M |
| Total debt | $160M | $188M | $232M | $252M | $59.6M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Xencor XNCR | $2.58B | +204% | +34% | -73% | 11.7× | n/a |
| Amgen AMGN | $240B | +34% | +9% | 36% | 7.2× | 1.6% |
| Genmab A/S GMAB.CO | $30.8B | +103% | +15% | 31% | 8.4× | 11.6% |
| Zymeworks ZYME | $1.81B | +5% | +98% | 17% | 8.9× | n/a |
| Janux Therapeutics JANX | $631M | -28% | +133% | -599% | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | $1.44B | -7% | +13% | -7% | 2.3× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | XNCR | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +37.9% | -4.0% | highest of 21 |
| 6-month return | +203.8% | -4.6% | highest of 21 |
| Distance from 52-week high | -15.3% | -32.5% | 5th highest of 21 |
| Revenue growth (TTM) | +33.5% | +9.4% | 4th highest of 17 |
| Operating margin | -72.7% | -2.6% | 6th lowest of 18 |
| EV / Sales | 11.7× | 7.7× | 7th most expensive of 17 |
| ROIC minus cost of capital | -45.3 pp | -6.5 pp | 3rd lowest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Xencor XNCR | United States | $2.58B | +204% | +34% | -73% | 11.7× | n/a | n/a |
| Xiamen Amoytop Biotech 688278.SS | China | $2.56B | -27% | +18% | 27% | 4.3× | -0.6% | +36.0% |
| MBX Biosciences MBX | United States | $2.65B | +70% | n/a | n/a | n/a | n/a | n/a |
| Walvax Biotechnology 300142.SZ | China | $2.48B | -26% | -23% | 5% | 9.4× | 29.5% | -3.8% |
| HLB 028300.KS | South Korea | $2.69B | -49% | +26% | -96% | 38.7× | n/a | n/a |
| Sunshine Lake Pharma 6887.HK | Hong Kong | $2.72B | -7% | +20% | -3% | 5.9× | n/a | n/a |
| Zai Lab 9688.HK | Hong Kong | $2.79B | +23% | 0% | -63% | 5.4× | n/a | n/a |
| Bavarian Nordic A/S BAVA.CO | Denmark | $2.82B | +23% | -8% | 18% | 2.6× | -4.3% | +27.4% |
| Hebei Changshan Biochemical Pharmaceutical 300255.SZ | China | $2.33B | -59% | 0% | -25% | 19.4× | n/a | n/a |
| XtalPi 2228.HK | Hong Kong | $2.87B | -34% | +4% | -127% | 21.3× | n/a | n/a |
| Arcus Biosciences RCUS | United States | $2.27B | -34% | -58% | -475% | 17.6× | n/a | n/a |
| Rubicon Research RUBICON.NS | India | $2.94B | +68% | +37% | 21% | 13.2× | n/a | n/a |
| Lakefront Biotherapeutics LKFT.AS | Netherlands | $2.26B | +31% | +223% | 64% | n/a | n/a | n/a |
| Denali Therapeutics DNLI | United States | $2.95B | -2% | n/a | -2,488% | 115.4× | n/a | n/a |
| Vimian VIMIAN.ST | Sweden | $2.26B | +51% | +8% | 19% | 5.0× | 13.4% | +44.5% |
| SKBS 302440.KS | South Korea | $2.25B | -12% | +11% | -23% | 4.3× | n/a | n/a |
| Dyne Therapeutics DYN | United States | $2.97B | -10% | n/a | n/a | n/a | n/a | n/a |
| Telix Pharmaceuticals TLX.AX | Australia | $2.99B | -2% | +27% | -1% | 3.8× | n/a | n/a |
| Pharvaris PHVS | United States | $2.21B | +7% | n/a | n/a | n/a | n/a | n/a |
| ADMA Biologics ADMA | United States | $3.01B | +58% | +6% | 45% | 6.0× | -0.8% | +64.6% |
| Beam Therapeutics BEAM | United States | $2.17B | -22% | +163% | -268% | 9.4× | n/a | n/a |